<DOC>
	<DOCNO>NCT00304005</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , VNP40101M , work different way stop growth cancer cell , either kill cell stop dividing . PURPOSE : This phase I/II trial study side effect best dose VNP40101M see well work treat patient Richter syndrome refractory relapse chronic lymphocytic leukemia lymphoproliferative disorder .</brief_summary>
	<brief_title>VNP40101M Treating Patients With Richter Syndrome Refractory Relapsed Chronic Lymphocytic Leukemia Other Lymphoproliferative Disorders</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) VNP40101M patient Richter syndrome refractory relapse chronic lymphocytic leukemia lymphoproliferative disease . ( phase I ) - Determine toxic effect drug patient . ( phase I ) - Determine efficacy , determine overall response rate , drug MTD determine phase I patient . ( phase II ) OUTLINE : This phase I dose-escalation study follow phase II study . - Phase I : Patients receive VNP40101M IV 30 minute day 1 . Courses repeat every 3-6 week 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos VNP40101M maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . - Phase II : Patients receive VNP40101M MTD determine phase I . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematologic malignancy : Fludarabine refractory relapse chronic lymphocytic leukemia ( CLL ) CLL transformation allow Richter syndrome Other refractory lymphoproliferative disease PATIENT CHARACTERISTICS : ECOG performance status 02 Creatinine ≤ 2.0 mg/dL Renal dysfunction due organ infiltration disease allow AST ALT ≤ 3 time upper limit normal ( ULN ) ( unless due organ infiltration disease ) Bilirubin ≤ 1.5 time ULN ( unless due Gilbert 's syndrome ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection No symptomatic coronary artery disease No arrhythmia control medication No uncontrolled , symptomatic congestive heart failure No myocardial infarction within past 3 month No uncontrolled illness No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : At least 2 week since prior cytotoxic therapy except patient rapidly progress disease No concurrent standard investigational treatment cancer No concurrent cytotoxic investigational drug No concurrent disulfiram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
</DOC>